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Abstract
This study aimed to demonstrate that microspheres, used as delivery vehicle of DNA-Hsp65/TDM
[plasmid DNA encoding heat shock protein 65 (Hsp65) coencapsulated with trehalose dimycolate
(TDM) into PLGA microspheres], are widely spread among several organs after intramuscular
administration in BALB/c mice. In general, we showed that these particles were phagocytosed by
antigen presenting cells, such as macrophages and dendritic cells. Besides, it was demonstrated
herein that draining lymph node cells presented a significant increase in the number of cells
expressing costimulatory molecules (CD80 and CD86) and MHC class II, and also that the
administration of the DNA-Hsp65/TDM and vector/TDM formulations resulted in the up-
regulation of CD80, CD86 and MHC class II expression when compared to control formulations
(vector/TDM and empty). Regarding the intracellular trafficking we observed that following
phagocytosis, the microspheres were not found in the late endosomes and/or lysosomes, until 15
days after internalization, and we suggest that these constructions were hydrolysed in early
compartments. Overall, these data expand our knowledge on PLGA [poly (lactic-co- glycolic acid)]
microspheres as gene carriers in vaccination strategies, as well as open perspectives for their
potential use in clinical practice.
Background
The encapsulation of DNA into biodegradable micro-
spheres such as those based on poly (lactic-co- glycolic
acid) copolymers (PLGA) provides an effective way to
protect the DNA against biological degradation by nucle-
ases and permits a continuous release of DNA in a con-
trolled manner over a period of time [1,2]. Besides, these
biocompatible and biodegradable copolymers have
already been approved for use in humans [3,4]. It has
been shown that PLGA microspheres have the potential to
act as mediators of DNA transfection targeted to phago-
cytic cells such as macrophages or dendritic cells [5-7].
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Previous studies have demonstrated that mice immunized
with microspheres containing plasmid DNA present an
immune response to the encoded antigens [8-10]. Our
laboratory has focused on intramuscular delivery of the
DNA-Hsp65 coencapsulated with trehalose dimycolate
(TDM) into PLGA microspheres (DNA-Hsp65/TDM) as a
vaccine against tuberculosis [11]. This procedure confers
protection against virulent M. tuberculosis challenge being
particularly effective in inducing the production of high
levels of IgG2a subtype antibody and high amounts of
IFN-γ. Furthermore, our group has previously shown that
this formulation also allowed a ten-fold reduction in the
DNA dose when compared to naked DNA-Hsp65 [11].
Although it is clear that encapsulated DNA can stimulate
immune response, other aspects of interest including the
microspheres distribution and persistence, as well as the
kind of cells involved in the uptake process after their in
vivo administration are poorly understood. PLGA micro-
spheres are thought to be internalized, in vitro, by phago-
cytic cells in a process dependent on their size range (1–
10 µm) [12-14], but only few studies were performed in
vivo to confirm this. The intraperitoneal injection of PLGA
microspheres leads to preferential phagocytosis by macro-
phages, whereas intradermal injection results in uptake of
these microspheres by dendritic cells [15]. It has already
been demonstrated that the inoculation site also interferes
with the biodistribution of DNA-loaded PLGA micropart-
icules [16]. However, the PLGA microspheres biodistribu-
tion has not yet been determined. Therefore, a better
understanding of the intracellular route and the biodistri-
bution of microspheres may contribute to improving their
efficacy and will be the basis for the development of new
vaccination strategies. In addition, the study of these
important questions in more detail is required to assure
the biosafety of microspheres allowing the advance of this
technology to a clinical setting against tuberculosis or in
veterinary vaccines. In this study we first evaluated the dis-
tribution of the PLGA microspheres containing DNA-
Hsp65/TDM and then addressed the cells involved in the
uptake process following the intramuscular administra-
tion. Finally, we have explored the fate of this formulation
inside peritoneal macrophages in order to better under-
stand the mechanisms involved in this process.
Methods
Plasmid construction
The pcDNA3-Hsp65 construct was derived from the
pcDNA3 vector (Invitrogen, Carlsbad, CA, USA), which
was digested with BamH I and Not I (Invitrogen), and a
3.3-kb fragment (corresponding to the M. leprae Hsp65
gene) was inserted. The vector pcDNA3 was used as a con-
trol. DH5α Escherichia coli, transformed with either
pcDNA3 plasmid or with the plasmid containing the
Hsp65 gene was cultured in LB medium (Gibco, Grand
Island, NY, USA) containing ampicilin (100 µg/mL, Cili-
non™). Plasmids were purified using the Endo-Free QIA-
GEN plasmid purification kit (QIAGEN AG, Basel,
Switzerland). Plasmid concentration was determined by
spectrophotometry at λ = 260 and 280 nm using the Gene
Quant II apparatus (Pharmacia Biotech, Buckingham-
shire, UK). The purity of DNA preparations was con-
firmed by electrophoresis on a 1% agarose gel. Endotoxin
levels were determined using a QCL-1000 Limulus amoe-
bocyte lysate kit (Cambrex Company, Walkersville, MD,
USA).
Microspheres preparation
Microspheres were prepared using the double emulsion/
solvent evaporation technique. Briefly, 30 ml of dichlo-
romethane solution containing 400 mg of polymer PLGA
50:50 (Resomer RG 505, MW 78 000, from Boehringer
Ingelheim, Ingelheim, Germany) and 0.5 mg of TDM
(Sigma Aldrich, St Louis, USA) was emulsified with 0.3 ml
of an inner aqueous phase containing 5 mg of DNA
(pcDNA3 or pcDNA3-Hsp65) using a T25 Ultraturrax
homogenizer (IKA, Labortechnik, Germany) to produce a
primary water-in-oil emulsion. This emulsion was then
mixed with 100 ml of an external aqueous phase contain-
ing 3% poly (vinyl alcohol) (Mowiols 40–88, Aldrich
Chemicals, Wankee, WI, USA) as surfactant, to form a sta-
ble water-in-oil-in-water emulsion. The mixture was
stirred for 6 h with a RW20N homogenizer (IKA) for sol-
vent evaporation. Microspheres were collected and
washed three times with sterile water, freeze-dried, and
stored at 4°C. Fluorescent-labeled microspheres were pre-
pared by adding 6-coumarin (green fluorescence; Sigma
Aldrich) to the organic phase. For flow cytometric analysis
and microscopy experiments, 6-coumarin/mg polymer
was used at doses of 16.5 µg and 0.15 µg, respectively.
Plasmid encapsulation efficiency was determined as
described by Barman et al. [17]. Briefly, 2.5 mg of micro-
spheres was resuspended in 0.5 ml of Tris-EDTA buffer,
pH 8.0. Chlorophorm, 0.5 ml, was added to the suspen-
sion to solubilize the microspheres. The mixture was
rotated end-over-end for 60 min at 37°C. The sample was
centrifuged at 14000 rpm for 5 min and 0.1 ml of the
supernatant was removed for analysis. The amount of
DNA (µg DNA extracted/mg polymer) was calculated
using the equation: DNA (µg/mg) = (Absorbanceλ = 260 nm
× dilution factor)/(εwb); where ε = 50-1 (extinction coeffi-
cient of DNA), w is weight of the microspheres in mg, b is
optical path length (1 cm).
Particle diameter distribution was evaluated by laser dif-
fractometry in a Cilas 1064 Liquid apparatus (Cilas,
France). Results are expressed as the median value of
diameter distribution.
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Immunization procedures
Young adult (6 weeks old) BALB/c mice were obtained
from the Animal Facilities of the School of Medicine of
Ribeirão Preto, University of São Paulo, and were main-
tained under standard laboratory conditions. Depending
on the objective of the experiment one of two protocols
was used using three or five animals per group. For biodis-
tribution experiments, mice received a single intramuscu-
lar injection of fluorescent microspheres (6-coumarin
labeled pcDNA3-Hsp65/TDM) dissolved in 50 µl saline
into each quadriceps muscle, whereas the control group
received microspheres without the fluorescent marker. For
all groups, the amount of microspheres injected was
determined based on the encapsulation efficiency rate in
order to comprise a 30 µg dose of plasmid (Table 1). At
various time points following the administration of
microspheres (from day 1 up to 120 days), total cells of
several tissues (draining lymph node, spleen, thymus,
lung, liver, kidney, testicle and single-cell suspension of
bone marrow) were obtained for FACS analysis as
described in theprocessing of tissues for biodistribution
experiments section. In the second protocol, to determine
the leukocyte subsets involved in the uptake process, mice
received a single dose of an intramuscular injection of 6-
coumarin labeled microspheres containing pcDNA3-
Hsp65/TDM, pcDNA3/TDM (microspheres containing a
total dose of 30 µg of plasmid) (Table 1) or empty micro-
spheres (5 mg of the polymer with empty formulation,
without plasmid DNA and TDM) (Table 1) in 50 µl saline
into each quadriceps muscle. After 7 days, the draining
lymph nodes were collected for FACS analysis. Control
group was injected with saline. The experiments were in
triplicata
Processing of tissues for biodistribution experiments
At various time points following the administration of
microspheres (from day 1 up to 120 days) several tissue
types were collected. Before FACS analysis, each tissue
received specific treatment in order to collect the total
cells. Briefly, the lung was sliced and incubated with 15 ml
of RPMI medium plus 1.25 µl of liberase (Roche – Indian-
apolis IN) for 20 min at 37°C. The sample was washed
with RPMI medium supplemented with 10% FCS and was
gently sieved to produce a cell suspension. Red blood cells
were lysed, the lung cells were treated with Desoxiribonu-
clease I 0.025% (Sigma-Aldrich – St Louis, USA) and then
used for FACS analysis. For liver and testicle, the tissues
were sliced, incubated in solution containing 10.8 mg of
colagenase IV (Sigma-Aldrich, USA), 22 mg of piruvate
(Vetec LTDA, Brazil), 3 mM of calcium chlorate (Sigma,
USA) and then submitted to similar procedures as
described above for lung. For kidney, the tissue was sliced,
incubated in solution containing 10.8 mg of colagenase
IV (Sigma-Aldrich, USA), 30 mg of tripsin (BD Difco,
USA), 3 mM of calcium chlorate, and then submitted to
similar procedures as described above for lung. For drain-
ing lymph node, spleen and thymus, the tissues were gen-
tly sieved to produce cell suspensions and the red blood
cells were lysed. After this, the cells were treated with Des-
oxiribonuclease I 0,025% (Sigma-Aldrich) and then used
for FACS analysis.
FACS analysis
To asses the biodistribution of the microspheres, an aliq-
uot of 1 × 106cells/tissue from the total cell preparation of
the each tissue types was washed three times with PBS and
ressuspended in 1% formaldehyde in PBS, and then ana-
lyzed by flow cytometry FACScan (Becton Dickinson, San
Jose, CA). The green fluorescence signal was analyzed by
flow cytometry using Fl-1 channel. For each analysis,
100.000 events were acquired. Analytical flow cytometry
was performed using a FACScan (Becton Dickinson, San
Jose, CA) and the data were analyzed using the WinMDI
software. Results are presented as adjusted percentages,
i.e., the background from controls (cells derived from
mice that received microspheres without fluorescent
marker) was subtracted from the positive percentage. To
determine the leukocyte subsets involved in the uptake
process, single-cell suspensions (1 × 106cells) isolated
from draining lymph nodes were collected and preincu-
bated with anti-CD16/CD32 (Fc Block- 2.4G2 PharMin-
gen, San Diego, CA) during 45 min at 4°C. Then, theses
cells were incubated with the specific phycoerythrin (PE)
labeled mAbs: anti-CD80, anti-CD86, anti-CD11b, anti-
CD11c or anti-CD IAd that was used as phycoerythrin
(PE)-conjugate (PharMingen, San Diego, CA) for 30 min
at 4°C. The cells were washed with 2% FCS in PBS, resus-
pended in PBS containing 1% formaldehyde and ana-
lyzed by flow cytometry. Analytical flow cytometry was
performed using a FACScan (Becton Dickinson, San Jose,
CA) and the data were analyzed using the WinMDI soft-
Table 1: Encapsulation efficiency and median diameter of 
different microsphere formulation
Microspheres Encapsulation 
efficiency
Values of diameter 
distribution 
(mean ± SD, µm)
pcDNA3-Hsp65/
TDM (6.6 mg 6-
coumarin)
49.9% (6.25 µg DNA/
mg of microspheres)
3.6 ± 0.27
pcDNA3/TDM (6.6 
mg 6-coumarin)
24% (3.0 µg DNA/mg 
of microspheres)
3.6 ± 0.29
pcDNA3-Hsp65/
TDM (60 µg 6-
coumarin)
52.8% (6.6 µg DNA/
mg of microspheres)
3.9 ± 0.25
pcDNA3-Hsp65/
TDM (without 6-
coumarin)
34.4% (4.3 µg DNA/
mg of microspheres)
3.6 ± 0.22
empty (6.6 mg 6-
coumarin)
--- 4.8 ± 0.32
Genetic Vaccines and Therapy 2007, 5:9 http://www.gvt-journal.com/content/5/1/9
Page 4 of 8
(page number not for citation purposes)
ware. As described above, the results are presented as
adjusted percentages, i.e., the background from the appro-
priate isotype controls was subtracted from the positive
percentage. Statistical determinations of the difference
among groups (pcDNA3-Hsp65/TDM, pcDNA3/TDM or
empty microspheres) were performed using one-way
analysis of variance (ANOVA) followed by Bonferroni
post test. All statistical tests were performed with the
GraphPad Prism 3.0 software (GraphPad Software Inc).
To calculate the mean fluorescence intensity (MFI)
increase, the empty microspheres MFI was normalized to
100% and pcDNA3-Hsp65/TDM and pcDNA3/TDM for-
mulations was then expressed as a percentage of empty
MFI. The values represented in the graphs are the mean ±
SD of three experiments.
Scanning confocal laser microscopy
Peritoneal macrophages (5 × 104 cells/wells) were plated,
24 h prior the experiment, on 8 well glass chamber slides
(Lab-Tek Chamber Slide System, Nalge Nunc Interna-
tional, Rochester, NY) in RPMI medium, without phenol
red, with 10% FCS. Cells were then treated with fluores-
cent microspheres (pcDNA3-Hsp65/TDM; 1 × 105 micro-
spheres/wells) at various time points (1, 5, 8 and 10 days),
and Texas Red dextran (10.000 MW, 10 µg/mL-Invitro-
gen, Molecular Probes, Inc., Carlsbad, CA; a marker for
late endosomes and lysosomes) was added for the last 24
hours. After this incubation, the cells were washed twice
with PBS, fixed for 15 minutes with 2% paraformaldehyde
in PBS and rinsed in PBS. Coverslips were mounted using
Fluormount (EM Sciences, Hatfield, PA) and examined by
confocal microscopy (Leica TCS SP5 AOBS – Leitz, Man-
heim, Germany).
Transmission electron microscopy
Peritoneal macrophages (1 × 106 cells/wells) were plated
in 36 mm tissue culture plates, 24 h prior the experiments,
in RPMI medium with 10% FCS and treated with fluores-
cent microspheres (pcDNA3-Hsp65/TDM; 2 × 106 micro-
spheres/wells) in growth medium at various time points
(1, 3, 5, 10 and 15 days). The cells were then washed with
PBS and fixed for 2 hours with 2% glutaraldehyde, 2%
paraformaldehyde in 0.1 M cacodylate buffer (pH: = 7.4).
After this, the cells were post-fixed in 2% osmium tetrox-
ide in 0.1 M cacodylate buffer (pH = 7.4) for 1 h, washed
with MilliQ water and stained en bloc 0.5% uranyl acetate
in water.. The samples were dehydrated in a graded series
of ethanol solutions (50%, 70%, 90%, 95%, 100%) and
infiltrated with propylene oxide. Lastly, the cells were
removed from the plates with propylene oxide and
embedded in Embed 812 (Electron Microscopy Sciences).
Ultrathin sections were cut using an ultramicrotome
(Reichert Ultracuts – Leica AG, Germany) and collected
on 200 mesh carbon coated copper grids. After staining
with uranyl acetate and counterstaining with lead citrate,
samples were observed with a transmission electron
microscope (Philips 410LS).
Results
Characterization of PLGA microspheres
The diameter (1 µm to 10 µm) of different PLGA formu-
lations used in this study presented Gaussian distribution,
with mean values ranging from 3.6 µm to 4.8 µm. The
DNA encapsulation efficiency ranged from 24% to 52.8%
(Table 1).
Biodistribution of PLGA microspheres after intramuscular 
delivery
FACS analysis was performed in order to investigate the
biodistribution of fluorescent PLGA microspheres after
intramuscular injection. Lymph node, spleen, thymus,
lung, liver, kidney, testicles and single-cell suspension of
bone marrow from each animal were harvested at various
time points. Our data revealed that the PLGA micro-
spheres presented a widespread distribution, since fluo-
rescent microspheres were detected in all organs analyzed
on days 1, 7 and 15 after intramuscular injection (Figure
1). Interestingly, variations in terms of biodistribution
were observed among the animals (Table 2 and Figure 1).
The microspheres remained in several tissues for extended
periods of time. In addition, several organs were still pos-
itive to fluorescent microspheres at 30, 60 and 120 after
injection, except liver and kidney at day 30, lymph node,
spleen and lung at day 60 and kidney at day 120. Lastly,
the number of cells containing fluorescent microspheres
in the lymph nodes was higher than that observed in
other organs (Figure 1).
Fluorescent PLGA microspheres were captured by antigen 
presenting cells after intramuscular administration
For FACS analysis, gates (forward and size scatter) were set
to eliminate non-ingested particles from the analyzed
population. Flow cytometric analysis of the draining
lymph node cells revealed that the microspheres were cap-
Table 2: Tissue distribution of PLGA microspheres after 
intramuscular administration
1d 7d 15d 30d 60d 120d
L Node 4 5 2 4 0 2
B Marrow 3 1 2 1 2 2
Spleen 5 3 2 2 0 1
Thymus 3 2 1 3 4 2
Lung 4 5 5 3 0 2
Kidney 4 3 3 0 5 0
Liver 5 2 3 0 5 2
Testicles 2 4 5 2 5 2
The numbers in the columns indicate the number of the animals that 
presented positive detection of fluorescent microspheres in each 
organ evaluated at 1, 7, 15, 30, 60 (n = 5 mice) and 120 (n = 3 mice) 
days after intramuscular administration.
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tured by CD11c+ cells and CD11b+ cells, most probably
dendritic cells and macrophages (Figure 2A). Moreover,
our results demonstrated that draining lymph node cells
derived from mice that had received the DNA-Hsp65/
TDM-containing formulation presented a significant
increase in the number of cells positive for cell surface
molecules CD80, CD86 and MHC class II versus the
groups that received the control formulations (vector/
TDM and empty) (Figure 2A). In addition, the administra-
tion of both DNA-Hsp65/TDM and vector/TDM formula-
tions resulted in the up-regulation of the median intensity
fluorescence (MIF) of CD80, CD86 and MHC class II
expression when compared with empty formulation (Fig-
ure 2B). Furthermore, DNA-Hsp65/TDM formulation
resulted in a significant increase in the MIF of CD86 and
MHC class II when compared with vector/TDM, while
CD80 MIF was also found to be increased in Hsp65/TDM
group, but this increase was not statistically significant.
The intracellular compartmentalization of fluorescent 
PLGA microspheres inside peritoneal macrophage
We next investigated the fate of fluorescent PLGA micro-
spheres after their uptake by peritoneal macrophages in
vitro. Dextran, a marker of late endosomes and lysosomes,
was used to localize the microspheres in these compart-
ments. As shown in Figure 3, fluorescent microspheres
were not co-localized with Texas Red dextran in the endo-
lysosomal compartments at any of the analyzed time (1,
5, 8 and 10 days). In addition, only small microspheres
were captured by peritoneal macrophages after 1 day of
treatment (Figure 3A–B, arrow), whereas small and large
microspheres were captured in other periods of time. It
was very interesting to observe intracellular hydrolysis of
microspheres inside macrophages after 5 days of incuba-
tion (Figure 3D, F and 3H, arrows). These results showing
the long lasting persistence of the microspheres inside the
cells during all time points analyzed (3, 5, 8, 10 and 15
days – Figure 4) were confirmed by transmission electron
microscopy (Figure 4).
Discussion
DNA-based vaccines have garnered attention for their
potential as an alternative treatment for infectious dis-
eases, however, usually multiple doses of high amounts of
naked plasmid DNA are required to elicit the desired pro-
tective response. Consequently, to optimize this vaccine
and reduce the amount of DNA, different methods of
delivery, such as gene gun, lipossomes, nano and micro-
particles, have been used. The encapsulation of the DNA
into PLGA microspheres represents an important tool to
target phagocytic cells contributing to the development of
an appropriate immune response. However, better under-
standing of the microspheres distribution is necessary to
achieve the goal of an effective immunization. With this
in mind, we used PLGA microspheres (DNA-Hsp65/
TDM), an efficient vaccine against tuberculosis [11], in
order to evaluate their distribution, the cells involved in
the uptake process and the fate of this formulation inside
peritoneal macrophages. For this purpose, PLGA micro-
spheres containing 6-coumarin, a useful fluorescence
microscopy probe that is not released from nanoparticles,
were used in this study [12].
Tissue distribution of PLGA microspheres after intramuscular administrationF g re 1
Tissue distribution of PLGA microspheres after intramuscular administration. Mice received a single intramuscular injection of 
fluorescent microspheres (DNA-Hsp65/TDM). At various time points (between 1 day and 120 days) the total cells from sev-
eral tissues (draining lymph node, spleen, thymus, lung, liver, kidney, testicle and single-cell suspension of bone marrow) were 
obtained for FACS analysis (for each analysis, 100.000 events were acquired). Each group consisted of three or five animals. 
The results were shown as the median of positive values for each time. ×: in this time the results were negative.
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In the first place, our results demonstrated that soon after
intramuscular administration the microspheres were
widely spread among several organs, which remained pos-
itive to fluorescent microspheres over a follow-up period
of 120 days. We hypothesized that this wide distribution
occurred via migration of phagocytic cells such as macro-
phages and dendritic cells, which had captured the micro-
spheres. However, we cannot exclude the possibility that
free microspheres might have drained from the injection
site into the lymphatics or systemic circulation reaching
distant sites where they would be engulfed by phagocytic
cells. On top of that, we showed that the number of cells
containing fluorescent microspheres in lymph nodes was
higher than that observed in other organs. Since lymph
nodes are the sites where adaptive immune responses to
lymph-antigens are initiated, our findings have far-reach-
ing implications for future research on vaccine design.
Despite the wide dissemination of microspheres through-
out the body and their long lasting persistence, previous
studies, carried out by our group, demonstrated that the
expression of mRNA specific for Hsp65 encapsulated into
microspheres (DNA-Hsp65/TDM) was sustained only for
15 days in muscle, liver, draining LN and spleen [11].
Intracellular compartmentalization of fluorescent PLGA microspheres inside peritone l macrophagFigur  3
Intracellular compartmentalization of fluorescent PLGA 
microspheres inside peritoneal macrophages. Confocal 
images of peritoneal macrophages incubated with fluorescent 
microspheres (green) for 1 day (A-B), 5 days (C-D), 8 days 
(E-F) and 10 days (G-H). Texas Red dextran was used as late 
endossome/lysosomal marker (red). Microspheres did not 
co-localize with Texas Red dextran in the endo-lysosomal 
compartment at any of the analyzed time (A, C, E and G). (B, 
D, F and H): Differential interference contrast microscopy of 
peritoneal macrophages incubated with microspheres plus 
Texas Red dextran. Arrows show intracellular hydrolysis of 
microspheres inside macrophages.
Fluorescent PLGA microspheres were captured by antigen presenting cells after intramuscular administrationigure 2
Fluorescent PLGA microspheres were captured by antigen 
presenting cells after intramuscular administration. To deter-
mine the leukocyte subsets involved in the uptake process, 
mice received a single intramuscular injection of 6-coumarin 
labeled microspheres containing DNA-Hsp65/TDM, vector/
TDM or empty microspheres (without plasmid DNA and 
TDM). After 7 days, the draining lymph nodes cells were col-
lected for FACS analysis (CD80, CD86, CD11b, CD11c and 
class II MHC). Control group was injected with saline. (A): 
Number of cells positive for cell surface molecules CD80, 
CD86 and MHC class II; *p < 0.05 versus control formula-
tions (vector/DMT and empty). (B): MFI increase expressed 
as a percentage from pcDNA3-Hsp65/TDM and pcDNA3/
TDM formulations, normalized to empty formulation. The 
values represented in the graphs are the mean ± SD of three 
experiments.
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After this time, Hsp65 mRNA was not detectable when
plasmid DNA encapsulated into microspheres was
administrated (data not shown). This fact can be due to
the decreased rate of the plasmid DNA delivery at later
time points, resulting in lower levels of Hsp65 message
that were not detectable in our RT-PCR assay. However,
the ability of PLGA microspheres to release the entrapped
plasmid DNA slowly indicates that this system is also able
to maintain the protein expression for long periods with-
out the need for booster vaccinations.
Similarly to previous observations for microspheres, our
group demonstrated that naked DNA (DNA-Hsp65) is
detectable in several tissue types, indicating that DNA-
Hsp65 is also widely disseminated throughout the body.
Notwithstanding, the Hsp65 mRNA was detected up to15
days only in muscle and liver tissues from immunized
mice [18].
Herein, we demonstrated for the first time that after intra-
muscular injection the microspheres were captured by
CD11c+ and CD11b+antigen presenting cells (APCs) from
lymph nodes. Furthermore, the mice that had received the
DNA-Hsp65/TDM-containing formulation presented a
significant increase in the number of APCs expressing
class II MHC and costimulatory molecules (CD80 and
CD86) in the lymph nodes. In addition, the expression of
class II MHC and CD86 was found to be significantly
upregulated (increased MFI) in the APCs from mice that
received DNA-Hsp65/TDM. Interestingly, the Vector/
TDM formulation also resulted in increased expression of
class II MHC and costimulatory molecules when com-
pared to empty formulation, but in a lower extent than
DNA-Hsp65/TDM. These results indicate that the upregu-
lation of these molecules was correlated with the presence
of Hsp65 protein, which possibly because of a synergistic
effect with the CpG motifs present in both the DNA-
Hsp65 and Vector constructions. It is possible that after
gene transcription the heat shock protein 65 (Hsp65)
stimulated phagocytic cells via their cell surface receptors.
This fact, which had not yet been described, is in agree-
ment with those reported previously where other Hsps
(gp96, Hsp70) are able to upregulate the costimulatory
molecules (CD80 and CD86) and MHC class II, probably
via Toll-like receptors (TLRs) 2 and 4 [19-21]. These find-
ings prompted the suggestion that TLRs could be involved
in the upregulation induced by Hsp65. However, we can-
not completely exclude that this upregulation can require
the cooperation of other receptors.
Interestingly, after intramuscular immunization a slight
variation in the number of microspheres was observed in
each organ. This difference may be the consequence of
some aspects such as inoculation pressure and/or mouse
variation.
The understanding of intracellular trafficking pathways of
both DNA vaccine and carrier is of particular relevance.
Our in vitro results indicate that the microspheres
remained in the cells until the last time analyzed (Figure
3 and Figure 4), pointing out a long lasting persistence.
Besides, only limited hydrolysis was observed in confocal
microscopy (Figure 4). Generally, phagocytozed particles
quickly move from early endosomes to late endosomes,
and then to the lysosomes. However, we observed that the
microspheres were not found in the late endosomes and/
or lysosomes, but probably remained retarded in other
vesicles, such as early endosomes, until 15 days after inter-
nalization suggesting that these constructions were hydro-
lysed in these vesicles. We propose that similar to other
delivery systems involving DNA complexed to synthetic
carrier molecules, such as cationic lipids or polymers [22-
25], the plasmid DNA was released into the cytoplasmatic
compartment. Based on our microscopy data we can infer
that the DNA was released into the cytoplasm, whereas
the carrier was not. In fact, in spite of evidences of low
degree of hydrolysis, which is supposed to allow the DNA
escape to cytoplasm, the microspheres remain in cells for
prolonged periods of time. It is important to consider that
the low rate of microspheres hydrolysis could result in
decreased release of DNA into the cytoplasm and there-
fore result in decreased efficiency of this formulation if
theoretically compared with faster release systems. On the
other hand, long lasting release of DNA could result in
prolonged immune response. Indeed, DNA release strate-
gies are extremely important and must be considered in
the rational design of appropriate delivery systems.
Micrographs of peritoneal macrophages after microspheres phag cytosiFigure 4
Micrographs of peritoneal macrophages after microspheres 
phagocytosis. Transmission electron microscopy of perito-
neal macrophages incubated with microspheres for 3 days 
(A), 5 days (B), 8 days (C), 10 days (D) and 15 days (E). 
Microspheres persisted inside the cells and remained in vesi-
cles during all the time points analyzed. (F): Peritoneal mac-
rophages without exposure to microspheres.
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Overall, our results demonstrated a wide biodistribution
of microspheres, which were preferentially concentrated
in the lymph nodes. These findings are of particular
importance since the activation of antigen presenting cells
can improve the development of specific immune
responses independent of the biodistribution. In fact, we
not only verified that the microspheres were taken up by
macrophages and dendritic cells but we also demon-
strated that lymph node cells presented a significant
increase in the expression of costimulatory molecules.
Likewise, we demonstrated for the first time that after
intramuscular administration the DNA-Hsp65/TDM-con-
taining formulation was internalized by antigen present-
ing cells from lymph nodes. It should be pointed out that
the long lasting permanence of the microspheres inside
APCs, observed herein, can contribute to the development
of an effective immune response without the need of fur-
ther immunizations. Taken together our results contribute
to a better understanding of microspheres as antigen car-
riers in vaccination strategies and provide additional pros-
pects for their use in clinical practice. The data reported
herein will be undoubtedly useful to the design of specific
carriers and consequently, to the development of an
improved vaccine against tuberculosis.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Acknowledgements
We thank Ms. Izaíra T. Brandão, Ms. Ana Paula Masson, Ms. Ana Flávia 
Gembre, Ms. Patrícia V.P. Palma, Maria Tereza P. Maglia and Ms. Márcia S.Z. 
Graeff for excellent technical assistance during the course of the studies. 
This study was supported by FAPESP and CNPq grants.
References
1. Wang D, Robinson DR, Kwon GS, Samuel J: Encapsulation of plas-
mid DNA in biodegradable poly(D, L-lactic-co-glycolic acid)
microspheres as a novel approach for immunogene delivery.
J Control Release 1999, 57:9-18.
2. Thomasin C, Corradin G, Men Y, Merkle HP, Gander B: Tetanus
toxoid and synthetic malaria antigen containing poly(lac-
tide)/poly(lactide-co-glycolide) microspheres: importance of
polymer degradation and antigen release for immune
response.  J Control Release 1996, 41:131-145.
3. Hanafusa S, Matsusue Y, Yasunaga T, Yamamuro T, Oka M, Shikinami
Y, Ikada Y: Biodegradable plate fixation of rabbit femoral shaft
osteotomies. A comparative study.  Clin Orthop Relat Res 1995,
315:262-271.
4. Mooney DJ, Sano K, Kaufmann PM, Majahod K, Schloo B, Vacanti JP,
Robert Langer: Long-term engraftment of hepatocytes trans-
planted on biodegradable polymer sponges.  J Biomed Mater Res
1997, 37:413-420.
5. Men Y, Audran R, Thomasin C, Eberl G, Demotz S, Merkle HP, Gan-
der B, Corradin G: MHC class I- and class II restricted process-
ing and presentation of microencapsulated antigens.  Vaccine
1999, 17:1047-1056.
6. Walter E, Dreher D, Kok M, Thiele L, Kiama SG, Gehr P, Merkle HP:
Hydrophilic poly(dl-lactide-co-gylcolide) microspheres for
the delivery of DNA to human-derived macrophages and
dendritic cells.  J Control Release 2001, 76:149-168.
7. Prior S, Gander B, Blarer N, Merkle HP, Subira ML, Irache JM,
Gamazo C: In vitro phagocytosis and monocyte-macrophage
activation with poly(lactide) and poly(lactide-co-glycolide)
microspheres.  Eur J Pharm Sci 2002, 15:197-207.
8. Hedley ML, Curley J, Urban R: Microspheres containing plasmid-
encoded antigens elicit cytotoxic T-cell responses.  Nat Med
1998, 4:365-368.
9. McKeever U, Barman S, Hao T, Chambers P, Song S, Lunsford L, Hsu
YY, Roy K, Hedley ML: Protective immune responses elicited in
mice by immunization with formulations of poly(lactide-co-
glycolide) microparticles.  Vaccine 2002, 20:1524-1531.
10. Hedley ML: Formulations containing poly(lactide-co-glycol-
ide) and plasmid DNA expression vectors.  Expert Opin Biol Ther
2003, 3:903-910.
11. Lima KM, Santos SA, Lima VMF, Coelho-Castelo AAM, Rodrigues JM
Jr, Silva CL: Single dose of a vaccine based on DNA encoding
mycobacterial hsp65 protein plus TDM-loaded PLGA micro-
spheres protects mice against a virulent strain of Mycobac-
terium tuberculosis.  Gene Therapy 2003, 10:678-685.
12. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL: The
mechanism of uptake of biodegradable microparticles in
Caco-2 cells is size dependent.  Pharm Res 1997, 14:1568-1573.
13. Walter E, Dreher D, Kok M, Thiele L, Kiama SG, Gehr P, Merkle HP:
Hydrophilic poly(DL-lactide-co-glycolide) microspheres for
the delivery of DNA to human-derived macrophages and
dendritic cells.  J Control Release 2001, 76:149-168.
14. Jilek S, Merkle HP, Walter E: DNA-loaded biodegradable micro-
particles as vaccine delivery systems and their interaction
with dendritic cells.  Adv Drug Deliv Rev 2005, 57:377-390.
15. Newman KD, Elamanchili P, Kwon GS, Samuel J: Uptake of poly(d,
l-lactic-co-glycolic acid) microspheres by antigen-presenting
cells in vivo.  J Biomed Mater Res 2002, 60:480-486.
16. Lunsford L, McKeever U, Eckstein V, Hedley ML: Tissue distribu-
tion and persistence in mice of plasmid DNA encapsulated in
PLGA-based microsphere delivery vehicle.  J Drug Target 2000,
8:39-50.
17. Barman SP, Lunsford L, Chambers P, Hedley ML: Two methods for
quantifying DNA extracted from poly(lactide-co-glycolide)
microspheres.  J Control Release 2000, 69:337-344.
18. Coelho-Castelo AMM, Trombone APF, Rosada RS, Santos RR Jr, Bon-
ato VLD, Sartori A, Silva CL: Tissue distribution of a plasmid
DNA encoding Hsp65 gene is dependent on the dose admin-
istered through intramuscular delivery.  Genetic Vaccines and
Therapy 2006, 4:1-10.
19. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK: Necrotic
but not apoptotic cell death releases heat shock proteins,
which deliver a partial maturation signal to dendritic cells
and activate the NF-kappa B pathway.  Int Immuno 2000,
12:1539-1546.
20. Singh-Jasuja H, Scherer HU, Norbert Hilf N, Arnold-Schild D, Ram-
mensee RG, Toes REM, Schild H: The heat shock protein gp96
induces maturation of dendritic cells and down-regulation of
its receptor.  Eur J Immunol 2000, 30:2211-2215.
21. Binder RJ, Vatner R, Srivastava P: The heat-shock protein recep-
tors: some answers and more questions.  Tissue Antigens 2004,
64:442-451.
22. Zelphati O, Szoka FCJr: Intracellular distribution and mecha-
nism of delivery of oligonucleotides mediated by cationic lip-
ids.  Pharm Res 1996, 13:1367-1372.
23. Mui B, Ahkong QF, Chow L, Hope MJ: Membrane perturbation
and the mechanism of lipid-mediated transfer of DNA into
cells.  Biochim Biophys Acta 2000, 1467:281-292.
24. Sonawane ND, Szoka FCJr, Verkman AS: Chloride accumulation
and swelling in endosomes enhances DNA transfer by
polyamine-DNA polyplexes.  J Biol Chem 2003, 278:44826-44831.
25. Lechardeur D, Verkman AS, Lukacs GL: Intracellular routing of
plasmid DNA during non-viral gene transfer.  Adv Drug Deliv
Rev 2005, 57:755-767.
